Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • NPPA revises rates of...

    NPPA revises rates of 6 drugs, fixes price of 1 medicine, check out details

    Written by Ruby Khatun Khatun Published On 2017-05-12T12:17:27+05:30  |  Updated On 12 May 2017 12:17 PM IST
    NPPA revises rates of 6 drugs, fixes price of 1 medicine, check out details




    New Delhi: Drug price regulator NPPA has revised the prices of six essential drugs, including the ones used for treatment of irritable bowel syndrome, and fixed the rate of one medicine.

    It has revised the prices of Dicyclomine injection, Erythromycin Estolate, Chloroquine Phosphate and their various strengths.

    Besides, it has fixed the price of P-PPi-L capsules which are used for treating acidity.

    "The NPPA has fixed/revised ceiling prices/retail prices of seven scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order,2016 under DPCO, 2013," the National Pharmaceutical Pricing Authority (NPPA) said in a notification today.

    As stipulated under the Drugs (Prices Control) Order (DPCO) 2013, the NPPA fixes ceiling price of essential medicines of Schedule I.

    In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually.

    The calculation for essential drugs is based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 per cent.

    The government had notified the DPCO 2013 with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs.

    Set up in 1997, NPPA has been entrusted with the task of fixing and revising prices of pharma products, enforcement of provisions of DPCO and monitoring the prices of controlled and decontrolled drugs.



    6 drugsacidityChloroquine PhosphateDicyclomine injectionDPCODrugs Prices Control OrderErythromycin Estolateirritable bowel syndromeNational Pharmaceutical Pricing AuthorityNPPAP-PPi-L capsulespricesrevises
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok